Sandoz, RareGen had more than one way of entering heart drug market, United Therapeutics says in motion to dismiss
MLex Summary: Sandoz and RareGen's joint complaint against United Therapeutics Corporation and Smiths Medical ASD should be dismissed because they failed to plead they were entirely foreclosed from the market for...To view the full article, register now.
Already a subscriber? Click here to view full article